Estrella Immunopharma Receives Coverage from Zacks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy ESLA?
Source: Newsfilter
- Zacks Coverage Initiation: Zacks Small-Cap Research has initiated coverage on Estrella Immunopharma, assigning a $12.00 per share valuation, highlighting the differentiation of its ARTEMIS platform and promising early clinical data, which may boost investor confidence.
- Clinical Trial Results: In the STARLIGHT-1 trial, all five evaluable patients achieved a 100% complete response rate at Month 1 among the nine patients, with no treatment-related serious adverse events reported, indicating EB103's potential in high-risk patients.
- Safety Profile Advantage: EB103 demonstrated a more favorable safety profile compared to existing CAR-T therapies in the Phase I trial, with all patients experiencing only low-grade Cytokine Release Syndrome (CRS) and no instances of Grade 3 or higher CRS, suggesting its clinical viability.
- ARTEMIS Platform Innovation: Zacks SCR describes the ARTEMIS platform as a potential next-generation evolution, emphasizing its ability to achieve more controlled T-cell activation through an antibody-TCR architecture, which may enhance Estrella's competitiveness in CAR-T innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESLA
About ESLA
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Estrella Immunopharma Receives Coverage from Zacks
- Zacks Coverage Initiation: Zacks Small-Cap Research has initiated coverage on Estrella Immunopharma, assigning a $12.00 per share valuation, highlighting the differentiation of its ARTEMIS platform and promising early clinical data, which may boost investor confidence.
- Clinical Trial Results: In the STARLIGHT-1 trial, all five evaluable patients achieved a 100% complete response rate at Month 1 among the nine patients, with no treatment-related serious adverse events reported, indicating EB103's potential in high-risk patients.
- Safety Profile Advantage: EB103 demonstrated a more favorable safety profile compared to existing CAR-T therapies in the Phase I trial, with all patients experiencing only low-grade Cytokine Release Syndrome (CRS) and no instances of Grade 3 or higher CRS, suggesting its clinical viability.
- ARTEMIS Platform Innovation: Zacks SCR describes the ARTEMIS platform as a potential next-generation evolution, emphasizing its ability to achieve more controlled T-cell activation through an antibody-TCR architecture, which may enhance Estrella's competitiveness in CAR-T innovation.
See More
Estrella Immunopharma Reports Positive STARLIGHT-1 Trial Results
- Clinical Trial Results: Estrella presented positive results from the STARLIGHT-1 trial at the 2026 ASTCT & CIBMTR meetings, where EB103 achieved a 100% complete response rate in the high-dose cohort, highlighting its potential in treating aggressive B-cell Non-Hodgkin Lymphoma.
- Sustained Patient Responses: All patients who achieved a complete response maintained their status at the data cutoff, with response durations ranging from 3 to 18 months, indicating EB103 may offer durable treatment effects for high-risk patients.
- Safety Profile: To date, the STARLIGHT-1 trial has reported no treatment-related serious adverse events, reinforcing EB103's potential as a
See More
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
- Stock Performance: STMicroelectronics shares rose 4.3% in pre-market trading to $31.13, indicating optimistic market sentiment regarding the company's future performance, which may attract more investor interest.
- Market Dynamics: The upward trend in STMicroelectronics' stock could influence the performance of other related tech stocks, particularly in the semiconductor sector, further boosting investor confidence in the industry.
- Investor Sentiment: As the stock price increases, investor sentiment may become more positive, leading to increased capital inflow and enhancing the company's market position.
- Future Outlook: The rise in STMicroelectronics' stock price may signal positive developments in the company's technological innovation and market demand, further solidifying its competitiveness in the global semiconductor market.
See More
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma has closed a registered direct offering with a single healthcare-focused institutional investor, issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, raising approximately $8 million, which enhances the company's financial resources for clinical development.
- Advancing Product Development: The proceeds will support the Phase II clinical trial of Estrella's lead product candidate, EB103, aimed at providing new treatment options for patients with cancers and autoimmune diseases who are not eligible for existing therapies, highlighting its significant clinical value.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating strong market confidence in Estrella's future growth, which may facilitate further advancements in the biopharmaceutical sector.
- Compliance and Transparency: The financing adheres to SEC registration requirements, ensuring compliance in all securities transactions, while the company commits to filing registration statements with the SEC, thereby enhancing investor trust in the company's transparency.
See More
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma closed a registered direct offering with a single healthcare-focused institutional investor, raising approximately $8 million by issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, thereby strengthening its financial position to support clinical objectives.
- Advancing Clinical Programs: The financing will provide Estrella with the necessary resources to advance its lead product EB103 into Phase II clinical trials, aimed at offering treatment options for cancer patients who are ineligible for currently marketed therapies, which holds significant market potential.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating market recognition of its ARTEMIS T-cell therapies, which may enhance future fundraising capabilities.
- Compliance Assurance: The offering was conducted under SEC registration statements, ensuring compliance, and through a registration rights agreement with the investor, Estrella will file registration statements to cover the resale of common stock, thereby boosting investor confidence.
See More
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
Estrella Immunopharma Receives Coverage from Zacks
- Zacks Coverage Initiation: Zacks Small-Cap Research has initiated coverage on Estrella Immunopharma, assigning a $12.00 per share valuation, highlighting the differentiation of its ARTEMIS platform and promising early clinical data, which may boost investor confidence.
- Clinical Trial Results: In the STARLIGHT-1 trial, all five evaluable patients achieved a 100% complete response rate at Month 1 among the nine patients, with no treatment-related serious adverse events reported, indicating EB103's potential in high-risk patients.
- Safety Profile Advantage: EB103 demonstrated a more favorable safety profile compared to existing CAR-T therapies in the Phase I trial, with all patients experiencing only low-grade Cytokine Release Syndrome (CRS) and no instances of Grade 3 or higher CRS, suggesting its clinical viability.
- ARTEMIS Platform Innovation: Zacks SCR describes the ARTEMIS platform as a potential next-generation evolution, emphasizing its ability to achieve more controlled T-cell activation through an antibody-TCR architecture, which may enhance Estrella's competitiveness in CAR-T innovation.
See More
Estrella Immunopharma Reports Positive STARLIGHT-1 Trial Results
- Clinical Trial Results: Estrella presented positive results from the STARLIGHT-1 trial at the 2026 ASTCT & CIBMTR meetings, where EB103 achieved a 100% complete response rate in the high-dose cohort, highlighting its potential in treating aggressive B-cell Non-Hodgkin Lymphoma.
- Sustained Patient Responses: All patients who achieved a complete response maintained their status at the data cutoff, with response durations ranging from 3 to 18 months, indicating EB103 may offer durable treatment effects for high-risk patients.
- Safety Profile: To date, the STARLIGHT-1 trial has reported no treatment-related serious adverse events, reinforcing EB103's potential as a
See More
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
- Stock Performance: STMicroelectronics shares rose 4.3% in pre-market trading to $31.13, indicating optimistic market sentiment regarding the company's future performance, which may attract more investor interest.
- Market Dynamics: The upward trend in STMicroelectronics' stock could influence the performance of other related tech stocks, particularly in the semiconductor sector, further boosting investor confidence in the industry.
- Investor Sentiment: As the stock price increases, investor sentiment may become more positive, leading to increased capital inflow and enhancing the company's market position.
- Future Outlook: The rise in STMicroelectronics' stock price may signal positive developments in the company's technological innovation and market demand, further solidifying its competitiveness in the global semiconductor market.
See More
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma has closed a registered direct offering with a single healthcare-focused institutional investor, issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, raising approximately $8 million, which enhances the company's financial resources for clinical development.
- Advancing Product Development: The proceeds will support the Phase II clinical trial of Estrella's lead product candidate, EB103, aimed at providing new treatment options for patients with cancers and autoimmune diseases who are not eligible for existing therapies, highlighting its significant clinical value.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating strong market confidence in Estrella's future growth, which may facilitate further advancements in the biopharmaceutical sector.
- Compliance and Transparency: The financing adheres to SEC registration requirements, ensuring compliance in all securities transactions, while the company commits to filing registration statements with the SEC, thereby enhancing investor trust in the company's transparency.
See More
Estrella Immunopharma Closes $8 Million Financing to Advance Clinical Trials
- Successful Financing: Estrella Immunopharma closed a registered direct offering with a single healthcare-focused institutional investor, raising approximately $8 million by issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants, thereby strengthening its financial position to support clinical objectives.
- Advancing Clinical Programs: The financing will provide Estrella with the necessary resources to advance its lead product EB103 into Phase II clinical trials, aimed at offering treatment options for cancer patients who are ineligible for currently marketed therapies, which holds significant market potential.
- Investor Confidence: The CEO stated that this financing underscores continued investor support for the company's clinical vision, indicating market recognition of its ARTEMIS T-cell therapies, which may enhance future fundraising capabilities.
- Compliance Assurance: The offering was conducted under SEC registration statements, ensuring compliance, and through a registration rights agreement with the investor, Estrella will file registration statements to cover the resale of common stock, thereby boosting investor confidence.
See More
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
See More
